Press Releases

Zoetis Inc . (NYSE:ZTS) today announced the acquisition of ZNLabs, a full-service veterinary clinical reference laboratory company with a network of labs across the U.S. This follows Zoetis’ recent acquisition of Phoenix Lab as its entry into reference laboratory services and builds on a strategy to develop a more comprehensive diagnostics offering with enhanced value for veterinarians in the U.S. Financial terms of the transaction are not being disclosed. Founded by veterinarians seeking to revolutionize reference laboratory services for companion animals, ZNLabs is guided by its mission to be “Simple. Friendly. Fair.” The company has differentiated itself by offering a simple test menu and fast results with friendly service and no contracts. ZNLabs operates a “hub” laboratory in Louisville, adjacent to a major logistics provider for fast sample turnaround times, with its “spoke” laboratories in Boise, Chicago, Cincinnati, Dallas, New Orleans and Salt Lake City providing local ...

Gives veterinarians a new choice for the treatment of mixed external and internal parasitic infestations Treats and has persistent efficacy against ticks and fleas for one month Treats gastrointestinal nematodes Prevents heartworm disease (Dirofilaria immitis) and lungworm disease (angiostrongylosis) Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted marketing authorisation for Simparica Trio™ (sarolaner/moxidectin/pyrantel) chewable tablets, a once-monthly triple combination antiparasitic medication for dogs with, or at risk from, mixed external and internal parasitic infestations. The granting of the marketing authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use on July 18, 2019. “The approval of Simparica Trio™ provides veterinarians a safe and effective option for the treatment of mixed external and internal parasitic infestations in dogs in the form of a new oral chewable,” said Dr. Domenico ...

Zoetis Inc . today announced that its scientists presented positive efficacy data for the company’s investigational, triple combination parasiticide product at the 2019 Triennial meeting of the American Heartworm Society (AHS) in New Orleans, La. Zoetis is developing a triple combination product containing sarolaner, moxidectin and pyrantel that is administered orally once a month as a preventative for heartworm disease and to treat and control ticks, fleas, and intestinal nematodes in dogs. The results from effectiveness studies in dogs treated with the combination product demonstrated that no adult heartworms were recovered from animals in the laboratory studies and no positive test results for adult heartworms were obtained from dogs in the field study. The product was well-tolerated in all studies presented. In addition, data from a separate study, which tested the efficacy of oral moxidectin at doses ranging from 3 to 60 µg/kg against three confirmed macrocyclic lactone resistant ...

Expands Point-of-Care diagnostic offerings to deliver more comprehensive equine health care Provides the convenience of a stall-side blood test PARSIPPANY, NEW JERSEY, AUGUST 15, 2019 – Today, Zoetis, the world’s leading animal health company, announced that it will expand its portfolio of products and services for horses with the Stablelab® hand-held, point-of-care diagnostic blood test, which provides veterinarians critical information related to equine inflammation in 10 minutes. The Stablelab hand-held reader detects and quantifies the biomarker Serum Amyloid A (SAA), which is a major, acute phase protein produced by the liver that rapidly and dramatically increases in response to inflammation caused by infection.   By measuring SAA, veterinarians can assess the severity of an infection sooner – often, before clinical symptoms start - and are able to monitor the horse’s response over the course of treatment.1 “Zoetis has always been committed to providing veterinarians and horse ...

Zoetis Inc. (NYSE: ZTS) today announced the completion of the acquisition of Platinum Performance, a privately-held nutrition-focused animal heath company, after fulfilling all closing requirements. The acquisition was first announced on July 22 and financial terms of the transaction are not being disclosed. “We are pleased to welcome the Platinum Performance team to Zoetis and together expand on the success of their high-quality, nutritional product formulas for horses, dogs and cats,” said Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy for Zoetis. “We look forward to coupling the expertise of Platinum’s colleagues and strength of the brand in the equine community with Zoetis’ global scale, resources and capabilities to drive increased focus on health and wellness as part of the continuum of animal care.” Platinum Performance was established in 1996 by Dr. Doug Herthel, DVM, and his son Mark Herthel, who will continue to ...

Zoetis, the leading global animal health company, today announced it is teaming up with actress and animal lover Kate Walsh 1 to help dogs feel their best and stay on their A-Game. The Show Us Your Dog’s A-Game campaign brings awareness to how skin diseases and allergies affect a dog’s well-being, and encourages pet owners to visit their veterinarians who can provide the right treatment to bring back their dogs’ A-Games. Timed with the inaugural “Itchy Pet Awareness Month” in August, Zoetis encourages dog owners to share photos or videos of their dogs’ A-Games on social media using the #MyDogsAGame hashtag. Each post will trigger a $10 donation2 by Zoetis Petcare (a U.S. business unit of Zoetis) to its K-9 Courage Program, which provides healthcare assistance to retired military and police dogs, as well as active service dogs that assist veterans suffering from post-traumatic stress. Posts may also be featured on an interactive gallery on www.MyDogsAGame.com, where dog owners can ...

Zoetis Inc. (NYSE: ZTS) today announced it has entered into an agreement to acquire Platinum Performance, a privately held, nutrition-focused animal health company. Platinum’s premium nutritional product formulas and unique approach to the field of scientific wellness for horses, dogs and cats will further strengthen and diversify Zoetis’ portfolio in the equine and petcare markets. Financial terms of the transaction are not being disclosed. Platinum’s flagship equine products include Platinum Performance® Equine, a comprehensive wellness and performance formula, and Platinum Performance® CJ, which delivers wellness and performance with the addition of joint support ingredients. Its petcare products include Platinum Performance® formulations that focus on wellness and joint support for dogs and cats. With the acquisition of Platinum’s premium quality, nutritional formulas, Zoetis is entering this space for horses and building on the company’s existing nutritional portfolio for dogs ...